Tumor infiltrated immune cell types support distinct immune checkpoint inhibitor outcomes in advanced non-small cell lung cancer Eur J Immunology 2021 Jan 28. doi: 10.1002
Efficacy of intravenous iron treatment for chemotherapy-induced anemia: A prospective Phase II pilot clinical trial in South Korea; PLoS Med 17(6): e1003091.https://doi.org/10.1371/journal.pmed.1003091
Concurrent genetic alterations predict the progression to target therapy in EGFR-mutated advanced non-small cell lung cancer in J Thorac Oncol. 2018 Oct 31. pii: S1556-0864(18)33383-5. doi: 10.1016
Comprehensive Clinical and Genetic Characterization of Hyperprogression Based on Volumetry in Advanced Non–Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitor ;J Thorac Oncol. Volume 14, Issue 9, Pages 1608–1618
Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib in Cancer Res Treat. 2018 Jun 13. doi: 10.4143/crt.2018.117.
High delta-like ligand 4 expression correlates with a poor clinical outcome in gastric cancer; J Cancer. 2019; 10(14): 3172–3178.
A Single Arm, Phase II Study of Simvastatin Plus XELOX and Bevacizumab as First-Line Chemotherapy in Metastatic Colorectal Cancer Patients; Cancer Research and Treatment > Volume 51(3); 2019, DOI: https://doi.org/10.4143/crt.2018.379
Adjuvant Chemotherapy with or without Concurrent Radiotherapy for Patients with Stage IB Gastric Cancer: a Subgroup Analysis of the Adjuvant Chemoradiotherapy in Stomach Tumors (ARTIST) Phase III Trial; J Gastric Cancer. 2018 Dec;18(4):348-355
MerTK inhibition by RXDX-106 in MerTK activated gastric cancer cell lines; Oncotarget. 2017 Dec 1; 8(62): 105727–105734.
Identification of FGFR3-TACC3 gene fusion in metastatic gastric cancer; Precis Future Med. 2017;1(4):168-172
Clinical trial of nintedanib in patients with recurrent or metastatic salivary gland cancer of the head and neck: A multicenter phase 2 study (Korean Cancer Study Group HN14-01): Nintedanib for Salivary Gland Cancer in CANCER 2017 Jun 1;123(11):1958-1964.
The Influence of Metastatic Lymph Node Ratio on the Treatment Outcomes in the Adjuvant Chemoradiotherapy in Stomach Tumors (ARTIST) Trial: A Phase III Trial; J Gastric Cancer. 2016 Jun;16(2):105-10
